Harvoni ledipasvir regulatory update

The U.K.’s NICE issued a preliminary appraisal recommending Harvoni ledipasvir/sofosbuvir from Gilead as a cost-effective treatment for certain subpopulations

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE